1887

Abstract

Summary

The antigenic sites recognized by monoclonal antibodies with neutralizing activity for the Sabin vaccine strains of poliovirus of serotypes 1, 2 and 3 have been studied by the isolation and characterization of mutants resistant to neutralization by antibody. Three distinct sites have been identified which are designated site 1, site 2 and site 3. Site 1 includes a region of 12 amino acids of VP1, from residues 89 to 100, and a corresponding region of VP1 has been identified as an antigenic site for poliovirus 2. This site was strongly immunodominant in type 2 and type 3 but was not detected for poliovirus 1. Site 2 is a complex site including residues 220 to 222 from VP1 (site 2a) with residues including 169 and 170 and others of VP2 (site 2b). Both site 2a and site 2b have been detected in type 1 poliovirus, while as yet only site 2b has been detected in type 3 poliovirus. Site 3 is a complex site including residues 286 to 290 from VP1 (site 3a) with residues including 58 and 59 and others of VP3 (site 3b). Both sites 3a and 3b have been detected in type 3 poliovirus, while as yet only site 3b has been detected in type 1 poliovirus.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-67-7-1283
1986-07-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/67/7/JV0670071283.html?itemId=/content/journal/jgv/10.1099/0022-1317-67-7-1283&mimeType=html&fmt=ahah

References

  1. Blondel B., Akacem O., Crainic R., Couillin P., Horodniceanu F. 1983; Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and heat inactivated virions. Virology 126:707–710
    [Google Scholar]
  2. Blondel B., Crainic R., Fichot O., Dufraisse G., Cardrea A., Girard M., Horaud F. 1986; Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody binding site. Journal of Virology 57:81–90
    [Google Scholar]
  3. Cann A. J., Stanway G., Hughes P. J., Minor P. D., Evans D. M. A., Schild G. C., Almond J. W. 1984; Reversion to virulence of the live attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Research 12:7787–7792
    [Google Scholar]
  4. Diamond D. C., Jameson B. A., Brown J., Kohara M., Abe S., Itoh H., Komatsu T., Arita M., Kuge S., Osterhaus A. D. M. E., Crainic R., Nomoto A., Wimmer E. 1985; Antigenic variation and resistance to neutralization in poliovirus type 1. Science 229:1090–1093
    [Google Scholar]
  5. Emini E. A., Jameson B. A., Lewis A. J., Larsen G. R., Wimmer E. 1982; Poliovirus neutralization epitopes: analysis and localization with neutralising monoclonal antibodies. Journal of Virology 43:996–1005
    [Google Scholar]
  6. Emini E. A., Jameson B. A., Wimmer E. 1984; Identification of a new neutralisation antigenic site on poliovirus coat protein VP2. Journal of Virology 52:719–721
    [Google Scholar]
  7. Evans D. M., Minor P. D., Schild G. S., Almond J. W. 1983; Critical role of an eight amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature, London 304:459–462
    [Google Scholar]
  8. Ferguson M., Minor P. D., Magrath D. I., Yi-Hua Qi., Spitz M., Schild G. C. 1984; Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. Journal of General Virology 65:197–201
    [Google Scholar]
  9. Ferguson M., Evans D. M. A., Magrath D. I., Minor P. D., Almond J. W., Schild G. C. 1985; Induction of broadly reactive, type specific neutralising antibody to poliovirus type 3 by synthetic peptides. Virology 143:505–515
    [Google Scholar]
  10. Fricks C. E., Icenogle J. P., Hogle J. M. 1985; Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles. Journal of Virology 54:856–859
    [Google Scholar]
  11. Hogle J. M., Chow M., Filman D. J. 1985; The three dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358–1365
    [Google Scholar]
  12. Kitamura N., Semler B. L., Rothberg P. G., Larsen G. R., Adler C. J., Dorner A. J., Emini E. A., Hanecak R., Lee J. L., Van Der Werf S., Anderson C. W., Wimmer E. 1981; Primary structure, gene organisation and polypeptide expression of poliovirus RNA. Nature, London 291:547–553
    [Google Scholar]
  13. Knossow M., Daniels R. S., Douglas A. R., Skehel J. J., Wiley D. C. 1984; Three dimensional structure of an antigenic mutant of the influenza virus haemagglutinin. Nature, London 311:678–680
    [Google Scholar]
  14. Le Bouvier G. L. 1959; The modification of poliovirus antigens by heat and ultraviolet light. Lancet ii:1013–1016
    [Google Scholar]
  15. Magrath D. I., Evans D. M. A., Ferguson M., Schild G. C., Minor P. D., Horaud F., Crainic R., Stenvik M., Hovi T. 1986; Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population. Journal of General Virology 67:899–905
    [Google Scholar]
  16. Minor P. D. 1980; Comparative biochemical studies of type 3 poliovirus. Journal of Virology 34:73–84
    [Google Scholar]
  17. Minor P. D., Schild G. C., Bootman J., Evans D. M. A., Ferguson M., Reeve P., Spitz M., Stanway G., Cann A. J., Hauptmann R., Clarke L. D., Mountford R. C., Almond J. W. 1983; Location and primary structure of a major antigenic site for poliovirus neutralization. Nature, London 301:674–679
    [Google Scholar]
  18. Minor P. D., Evans D. M. A., Ferguson M., Schild G. C., Westrop G., Almond J. W. 1985; Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. Journal of General Virology 66:1159–1165
    [Google Scholar]
  19. Rossmann M. G., Arnold E., Erickson J. W., Frankenberger E. A., Griffith J. P., Hecht H. J., Johnson J. E., Kramer G., Luo Ming, Mosser A. G., Rueckert R. R., Sherry B., Vriend G. 1985; The Structure of a human common cold virus (rhinovirus 14) and its functional relations to other picomaviruses. Nature, London 317:145–153
    [Google Scholar]
  20. Sabin A. B., Boulger L. R. 1973; History of Sabin attenuated poliovirus oral live vaccine strains. Journal of Biological Standardization 1:115–118
    [Google Scholar]
  21. Salk J., Salk D. 1977; Control of influenza and poliomyelitis with killed virus vaccines. Science 195:834–835
    [Google Scholar]
  22. Sherry B., Rueckert R. 1985; Evidence for at least two dominant neutralization antigens on human rhinovirus 14. Journal of Virology 53:137–143
    [Google Scholar]
  23. Toyoda H., Kohara M., Katadia Y., Suganuma T., Omata T., Imura N., Nomoto A. 1984; Complete nucleotide sequence of all three poliovirus serotype genomes. Implication for genetic relationships, gene function and antigenic determinants. Journal of Molecular Biology 174:561–585
    [Google Scholar]
  24. Van Der Werf S., Wychowski C., Bruneau P., Blondel B., Crainic R., Horodniceanu F., Girard M. 1983; Localization of a poliovirus type 1 neutralization epitope in viral capsid polypeptide VP1. Proceedings of the National Academy of Sciences, U.S.A. 80:5080–5084
    [Google Scholar]
  25. World Health Organization Report 1981; Markers of poliovirus strains isolated from cases temporally associated with the use of live poliovirus vaccine: report on a WHO collaborative study. Journal of Biological Standardization 9:163–184
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-67-7-1283
Loading
/content/journal/jgv/10.1099/0022-1317-67-7-1283
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error